Skystar Bio-pharmaceutical Co. (fka SKBI)

[236T568]

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

On December 17, 2015, Skystar Bio-Pharmaceutical Company (the “Company”) received a notification from The Nasdaq Stock Market (“Nasdaq”) informing the Company that a Nasdaq hearing panel had decided to delist the Company’s shares from Nasdaq and that the Company’s shares would be suspended from trading on Nasdaq at the open of business on December 21, 2015.

The Company previously disclosed a notification from Nasdaq informing the Company that is was subject to delisting because it failed to comply with Nasdaq’s filing requirements set forth in Listing Rule 5250(c)(1) because it failed to file its Form 10-K for the fiscal year ended December 31, 2014, and Forms 10-Q for the periods ended March 31, and June 30, 2015. The failure to file the Quarterly Report constitutes an additional basis for delisting. The Company also previously disclosed that Nasdaq had notified the Company of two additional, and separate, bases for delisting under Listing Rule 5250(b)(1) (failure to disclose material non-public information) and Listing Rule 5101 (public interest concerns).


http://ih.advfn.com/p.php?pid=nmona&article=69760863&symbol=SKBI